G1 Therapeutics Stock Price, News & Analysis (NASDAQ:GTHX) $2.00 0.00 (0.00%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$1.93▼$2.1150-Day Range$1.12▼$2.0052-Week Range$1.08▼$8.40Volume871,055 shsAverage Volume905,050 shsMarket Capitalization$103.68 millionP/E RatioN/ADividend YieldN/APrice Target$11.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability G1 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside490.0% Upside$11.80 Price TargetShort InterestBearish4.80% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.96) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 starsMedical Sector725th out of 952 stocksPharmaceutical Preparations Industry342nd out of 434 stocks 3.3 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.80, G1 Therapeutics has a forecasted upside of 490.0% from its current price of $2.00.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.80% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in G1 Therapeutics has recently increased by 2.05%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 1.1 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for G1 Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.23% of the stock of G1 Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.04% of the stock of G1 Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($0.96) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About G1 Therapeutics Stock (NASDAQ:GTHX)G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comG1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer SymposiumNovember 11, 2023 | finance.yahoo.comWhen Will G1 Therapeutics, Inc. (NASDAQ:GTHX) Turn A Profit?December 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 3, 2023 | bizjournals.comChemotherapy shortage slams RTP firm's revenue projectionsNovember 2, 2023 | nasdaq.comG1 Therapeutics (GTHX) Price Target Increased by 7.95% to 9.69November 2, 2023 | finance.yahoo.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call TranscriptNovember 1, 2023 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Reports Q3 2023 Earnings: $12.3 Million in Total RevenueNovember 1, 2023 | finance.yahoo.comG1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational HighlightsDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 31, 2023 | benzinga.comEarnings Preview For G1 TherapeuticsOctober 31, 2023 | msn.comG1 Therapeutics Q3 2023 Earnings PreviewOctober 27, 2023 | finance.yahoo.comReal World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)October 25, 2023 | finance.yahoo.comWill G1 Therapeutics (GTHX) Report Negative Earnings Next Week? What You Should KnowOctober 18, 2023 | finance.yahoo.comG1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023October 18, 2023 | finance.yahoo.comG1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)October 16, 2023 | finance.yahoo.comG1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care SymposiumOctober 7, 2023 | msn.comJP Morgan Downgrades G1 Therapeutics (GTHX)October 6, 2023 | msn.comG1 Therapeutics downgraded at JPMorgan on potential Q3 missSeptember 5, 2023 | finance.yahoo.comG1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 4, 2023 | msn.comWedbush Reiterates G1 Therapeutics (GTHX) Outperform RecommendationAugust 3, 2023 | msn.comNeedham Maintains G1 Therapeutics (GTHX) Buy RecommendationAugust 2, 2023 | finance.yahoo.comG1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational HighlightsAugust 1, 2023 | markets.businessinsider.comG1 Therapeutics earnings: here's what Wall Street expectsJuly 31, 2023 | finance.yahoo.comG1 Therapeutics to Participate in Two August Investor ConferencesJuly 31, 2023 | finance.yahoo.comNew Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)July 27, 2023 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are individual investors with 46% stake, while 38% is held by institutionsJuly 26, 2023 | finance.yahoo.comG1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023See More Headlines Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees170Year FoundedN/APrice Target and Rating Average Stock Price Target$11.80 High Stock Price Target$19.00 Low Stock Price Target$5.00 Potential Upside/Downside+490.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-147,560,000.00 Net Margins-90.82% Pretax Margin-87.36% Return on Equity-132.03% Return on Assets-44.85% Debt Debt-to-Equity Ratio1.19 Current Ratio3.75 Quick Ratio3.35 Sales & Book Value Annual Sales$51.30 million Price / Sales2.02 Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book1.25Miscellaneous Outstanding Shares51,840,000Free Float47,577,000Market Cap$103.68 million OptionableOptionable Beta1.81 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. John E. Bailey Jr. (Age 58)CEO, President & Director Comp: $1.06MMr. Mark Avagliano (Age 47)Chief Business Officer Comp: $628.54kMr. John W. Umstead V (Age 38)Chief Financial Officer Mr. Terry L. Murdock (Age 63)Chief Operating Officer Comp: $541.59kMr. William C. Roberts (Age 54)Vice President of Investor Relations & Corporate Communications Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerMr. Evan Hicks M.B.A.Vice President of MarketingDr. Rajesh K. Malik Ch.B. (Age 64)M.B., M.D., Chief Medical Officer Comp: $596.37kMr. Andrew Perry (Age 50)Chief Commercial Officer Comp: $568.6kMr. Jeff MacdonaldSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsOramed PharmaceuticalsNASDAQ:ORMPReviva PharmaceuticalsNASDAQ:RVPHIO BiotechNASDAQ:IOBTAcrivon TherapeuticsNASDAQ:ACRVSagimet BiosciencesNASDAQ:SGMTView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Bought 80,480 shares on 11/17/2023Ownership: 1.106%Ameriprise Financial Inc.Sold 89,334 shares on 11/15/2023Ownership: 0.073%GSA Capital Partners LLPSold 246,651 shares on 11/15/2023Ownership: 0.037%Connor Clark & Lunn Investment Management Ltd.Bought 82,879 shares on 11/13/2023Ownership: 0.394%Algert Global LLCBought 68,100 shares on 11/13/2023Ownership: 0.131%View All Insider TransactionsView All Institutional Transactions GTHX Stock Analysis - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price target for 2024? 6 equities research analysts have issued 1-year price objectives for G1 Therapeutics' stock. Their GTHX share price targets range from $5.00 to $19.00. On average, they predict the company's stock price to reach $11.80 in the next year. This suggests a possible upside of 490.0% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2023? G1 Therapeutics' stock was trading at $5.43 at the start of the year. Since then, GTHX stock has decreased by 63.2% and is now trading at $2.00. View the best growth stocks for 2023 here. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, November, 1st. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.04. The firm earned $12.30 million during the quarter, compared to analysts' expectations of $13.73 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 132.03% and a negative net margin of 90.82%. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? (GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Raymond James & Associates (1.79%), Jacobs Levy Equity Management Inc. (1.11%), Connor Clark & Lunn Investment Management Ltd. (0.39%), Denali Advisors LLC (0.29%), Acadian Asset Management LLC (0.25%) and Franklin Street Advisors Inc. NC (0.16%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GTHX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.